Related Experiment Video

Updated: Aug 21, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

[Angiotensin converting enzyme and left ventricular hypertrophy in uremic patients: correlation and therapeutic

Senija Rasić1, Amra Catović, Jasmin Huskić

  • 1Institut za nefrologiju, Klinicki centar Univerziteta Sarajevo, Sarajevo, Bosna i Hercegovina.

Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti
|October 27, 2004
PubMed

Insights

Anemia treatment with erythropoietin in hemodialysis patients reduced left ventricular hypertrophy and angiotensin-converting enzyme activity. This suggests a link between renal anemia, cardiac remodeling, and ACE levels.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Context:

  • Anemia is a common complication of chronic kidney disease and a contributor to left ventricular hypertrophy (LVH).
  • The renin-angiotensin-aldosterone system, particularly angiotensin-converting enzyme (ACE), plays a role in cardiac remodeling.
  • Erythropoietin therapy is standard for anemia in hemodialysis patients.

Purpose:

  • To investigate the association between serum ACE activity and LVH in hemodialysis patients with anemia.
  • To evaluate the effect of human recombinant erythropoietin (rHuEpo) treatment on serum ACE activity and LV geometry over six months.

Summary:

  • Serum ACE activity was significantly higher in hemodialysis patients with LVH compared to those with normal LV mass.
  • A positive correlation was observed between ACE activity and LV mass index.
  • Six months of rHuEpo treatment led to significant reductions in both LV mass index and serum ACE activity.

Impact:

  • Serum ACE activity levels are linked to left ventricular geometry in hemodialysis patients.
  • rHuEpo therapy may offer a dual benefit by improving renal anemia, reducing LV mass, and modulating ACE activity.
Abstract

More Related Videos

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...